Fremanezumab for Preventive Treatment of Migraine

Neurology - United States
doi 10.1212/01.wnl.0000544321.19316.40
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine

Pain and Therapy
NeurologyAnesthesiologyPain Medicine
2020English

Population Pharmacokinetic Modeling and Simulation of Fremanezumab in Healthy Subjects and Patients With Migraine

British Journal of Clinical Pharmacology
Pharmacology
2019English

Pnd67 - Are New Preventive Migraine Drugs Cost-Effective for Patients With Chronic and Episodic Migraine for Whom Other Preventive Medications Had Failed?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd141 - Characteristics and Management of Migraine Patients Who Have Failed Prior Preventive Treatment in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Treatment Options for Vestibular Migraine

US Neurology
NeuroscienceNeurology
2016English

Treatment of Migraine.

BMJ
1978English

Acute Migraine Treatment - Information for Patients

Canadian Journal of Neurological Sciences
MedicineNeurology
2013English

CSD-induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine With Aura

Journal of Neuroscience
Neuroscience
2019English

Pnd6 - Characterization of Preventive Treatment in Episodic and Chronic Migraine Patients Managed by General Practitioners in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy